Technical Analysis for SBBP - Strongbridge Biopharma plc
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| See historical SBBP trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 19 | New Uptrend | Bullish | 0.00% |
| Mar 15 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 5.08% |
| Mar 15 | Outside Day | Range Expansion | 5.08% |
| Mar 13 | Stochastic Reached Overbought | Strength | 4.10% |
| Mar 13 | Overbought Stochastic | Strength | 4.10% |
| Mar 12 | Upper Bollinger Band Walk | Strength | 4.49% |
| Mar 12 | Upper Bollinger Band Touch | Strength | 4.49% |
| Mar 11 | Crossed Above 200 DMA | Bullish | 1.27% |
| Mar 11 | Expansion Breakout | Bullish Swing Setup | 1.27% |
| Mar 11 | Pocket Pivot | Bullish Swing Setup | 1.27% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-02-26
- Sector: Healthcare
- Industry: Biopharmaceuticals
Strongbridge Biopharma plc, a biopharmaceutical company, through its subsidiary, Cortendo AB (publ), develops, acquires, and commercializes product candidates that target rare diseases. The company's lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is in the Phase 3 trial for the treatment of endogenous Cushing's syndrome. It also has two product candidates, COR-004 and COR-005 in Phase 2 clinical development to treat acromegaly. In addition, it is developing BP-2001, a pre-clinical product candidate for the treatment of diabetes. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Chemistry Biopharmaceutical Organ Systems Chemical Compounds Diabetes Rare Diseases Chloroarenes Treatment Of Diabetes Acromegaly Cushing's Syndrome Adrenal Gland Disorders Cortisol Endogenous Cushing's Syndrome Piperazines
Chemistry Biopharmaceutical Organ Systems Chemical Compounds Diabetes Rare Diseases Chloroarenes Treatment Of Diabetes Acromegaly Cushing's Syndrome Adrenal Gland Disorders Cortisol Endogenous Cushing's Syndrome Piperazines
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more SBBP news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 9.25 |
| 52 Week Low | 3.82 |
| Average Volume | 145,089 |
| 200-Day Moving Average | 5.1221 |
| 50-Day Moving Average | 4.925 |
| 20-Day Moving Average | 5.175 |
| 10-Day Moving Average | 5.318 |
| Average True Range | 0.2295 |
| ADX | 26.08 |
| +DI | 31.3214 |
| -DI | 11.4993 |
| Chandelier Exit (Long, 3 ATRs ) | 5.0015 |
| Chandelier Exit (Short, 3 ATRs ) | 5.1885 |
| Upper Bollinger Band | 5.7146 |
| Lower Bollinger Band | 4.6354 |
| Percent B (%b) | 0.88 |
| BandWidth | 20.854106 |
| MACD Line | 0.1722 |
| MACD Signal Line | 0.15 |
| MACD Histogram | 0.0222 |
| Fundamentals | Value |
|---|---|
| Market Cap | 197.52 Million |
| Num Shares | 35.3 Million |
| EPS | -2.93 |
| Price-to-Earnings (P/E) Ratio | -1.91 |
| Price-to-Sales | 139.82 |
| Price-to-Book | 21.76 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.98 | ||||
| Resistance 3 (R3) | 5.97 | 5.83 | 5.92 | ||
| Resistance 2 (R2) | 5.83 | 5.73 | 5.84 | 5.89 | |
| Resistance 1 (R1) | 5.71 | 5.67 | 5.77 | 5.72 | 5.87 |
| Pivot Point | 5.57 | 5.57 | 5.60 | 5.58 | 5.57 |
| Support 1 (S1) | 5.45 | 5.47 | 5.51 | 5.46 | 5.31 |
| Support 2 (S2) | 5.31 | 5.41 | 5.32 | 5.29 | |
| Support 3 (S3) | 5.19 | 5.31 | 5.27 | ||
| Support 4 (S4) | 5.20 |
